Hubei Haizi Pharmaceutical

Hubei Haosun Pharmaceutical is a leading Chinese pharmaceutical company specializing in the development and large-scale manufacturing of high-potency active pharmaceutical ingredients (APIs), with a primary focus on oncology. Based in Xiangyang, Hubei Province, the company operates state-of-the-art facilities that comply with international quality standards, including US FDA, EU GMP, and Chinese GMP certifications. Their product portfolio includes critical small molecule chemotherapeutics such as docetaxel, paclitaxel, irinotecan, and gemcitabine. Haosun serves as a key global supplier for finished dosage form manufacturers, providing high-quality raw materials for cancer treatments and other therapeutic areas. The company is recognized for its expertise in complex chemical synthesis and its commitment to environmental and safety standards in pharmaceutical production.